Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.64 |
| ▸ | FAAH | O00519 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 2/20 | 0.62 |
| ▸ | MLLT1 | Q03111 | 5/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.56 |
| ▸ | MLLT3 | P42568 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1474935 | 0.88 | FAAH (0.81) | MAPTFAAHRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1476381 | 0.88 | RAB9A (0.63) | MAPTFAAHRAB9AMLLT1SMN1; SMN2 | |
| SCHEMBL1474724 | 0.88 | MAPT (0.63) | MAPTFAAHRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL1476073 | 0.88 | MAPT (0.63) | MAPTFAAHRAB9ASMN1; SMN2TP53 | |
| SCHEMBL1475159 | 0.87 | FAAH (0.68) | MAPTFAAHRAB9ATP53ALDH1A1 | |
| SCHEMBL1474441 | 0.85 | MAPT (0.75) | MAPTFAAHRAB9ASMN1; SMN2TP53 | |
| SCHEMBL1474570 | 0.85 | FAAH (0.62) | MAPTFAAHRAB9ASMN1; SMN2TP53 | |
| SCHEMBL1476525 | 0.84 | MAPT (0.59) | MAPTFAAHRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL15190341 | 0.83 | MAPT (0.44) | MAPTFAAHRAB9AMLLT1SMN1; SMN2 | |
| SCHEMBL1474540 | 0.81 | FAAH (0.67) | MAPTFAAHRAB9ASMN1; SMN2TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-7915297-B2 | Isoxazole derivatives and use thereof | SK HOLDINGS CO., LTD. (KR) | 2011-03-29 | — | — | US | disclosed |
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | SK BIOPHARMACEUTICALS CO., LTD. (KR) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131336-A1 | Isoxazole Derivatives and Use Thereof | WNT3A, WNT1, WNT3 | MAPT 2497/4885FAAH 4712/4885RAB9A 2013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.